Ultra-low-dose desogestrel ethinyl estradiol tablets are derived from the Mafulon brand, a world-renowned short-acting oral contraceptive, a widely used oral contraceptive brand with ultra-low estrogen content in short-acting contraceptives
Mafulon is the leader of the modern global short-acting contraceptive, which has a history of many years, and has a high degree of contraceptive reliability, making it a safe choice for couples in 97 countries around the world, helping you stay away from the worry of unplanned pregnancy. In 1994, the Mafulon oral contraceptive pill was brought to China by the Dutch pharmaceutical company Organon.
Mafulon entered Europe in 1981 and has become one of the most widely used brands of oral contraceptives in the world. Because of its unique progesterone composition, Mafulon overcomes the androgenic side effects of previous domestic oral contraceptives, and the incidence of other side effects is very low. In developed countries in Europe and the United States, the use of oral contraceptives among women of childbearing age has been very high, between 30% and 40%. Currently, about 75 million women worldwide are taking Mafulon, and its use has become so widespread that it was approved by the U.S. Food and Drug Administration (FDA) in 1992. Sold well in 114 countries and regions around the world. As of 1998, the global sales volume of Mafulon has exceeded 900 million boards.
On March 12, 2007, Schering-Plough Corporation (NYSE: SGP) announced that its Board of Directors approved a transaction. UNDER THE DEAL, SCHERING-PLOUGH WILL ACQUIRE ORGANON BIOTECHNOLOGY, THE HUMAN PHARMACEUTICALS AND ANIMAL HEALTH PRODUCTS BUSINESS OF AKZO-NOBEL, FOR APPROXIMATELY €11 BILLION IN CASH ($14.4 BILLION BASED ON THE CLOSING EXCHANGE RATE ON MARCH 9, 2007). This transaction is an important milestone in the history of the development of Mafulon, an excellent contraceptive pill.
On May 8, 2014, Bayer officially entered into a partnership with Merck & Co., Ltd. (MRK. NYSE, known as Merck in the U.S. and Canada), has reached a definitive agreement to acquire the latter's consumer health business for $14.2 billion, which includes its star products, the anti-allergy drug Claritin and the nasal vasoconstrictor drug Afrin.
